Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.2852W HIGH $13.11
Volume
110.85 K
Value Traded
1.02 M
Short % Float
-
Days to Cover
1.0
-6.67%Week
-12.68%1 Month
-21.31%3 Month
-10.21%6 Month
-40.78%5 Year
-40.78%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.14 B
EPS (TTM)
-0.02
P/E Ratio
-
Ent. Value
3.55 B
Total Shares
339.78 M
Float Shares
-
Insiders
-
Institutions
1.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TLX Catalyst Timeline
Dated clinical, regulatory and corporate events for Telix Pharmaceuticals Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Telix Pharmaceuticals Limited
831Total events
38Upcoming
246Tier-1 (high impact)
2017 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Telix and Ekalia announce collaboration for U.S. astatine-211 production
◆Oral PresentationTLX250-CDx (Zircaix)FiledPresentation
ELEGANCE pilot study of TLX250-Px PET/CT presented at EANM
Hepatocellular Carcinoma, Biliary Tract Cancer or Gastro-Entero-Pancreatic Neuroendocrine Neoplasmssource ↗
◆Oral PresentationTLX591FiledPresentation
HIMIKO TLX591-Px PET/CT in HCC presented at EANM
Hepatocellular Carcinomasource ↗
◆Oral PresentationTLX-250Presentation
LUTEON Phase 3 TLX250-Tx study presented at EANM
advanced, relapsed or recurrent ccRCCsource ↗
●R&D DayPresentation
Telix sponsored symposium on theranostics in urologic oncology at EANM
urologic oncology theranosticssource ↗
◆Poster PresentationTLX591FiledPresentation
Illuccix China Phase 3 preliminary results of TLX591-Px PET presented at EANM
biochemical recurrence of prostate cancersource ↗
◆Poster PresentationTLX250-CDx (Zircaix)FiledPresentation
TLX250-Px PET/CT impact on staging and clinical management in ccRCC presented at EANM
clear cell renal cell carcinomasource ↗
◆Poster PresentationTLX102Presentation
QDOSE allometry-guided dosimetry of TLX102-Tx presented at EANM
▲Partnership / LicenseCorporate
Profound Medical and Telix enter co-education agreement for PSMA-informed prostate care
prostate cancersource ↗
▲Product LaunchPixclaraApprovedPost-Market
Start of U.S. commercial availability for Pixclara
glioma (brain cancer) imagingsource ↗
▲First Patient DosedPixclaraApprovedTrial
First patients dosed with Pixclara in the U.S. (Cleveland, OH and Indianapolis, IN)
glioma (brain cancer) imagingsource ↗
◆Poster PresentationTLX591FiledPresentation
Illuccix China preliminary Phase 3 results of TLX591-Px PET in Chinese men ePoster at EANM
biochemical recurrence of prostate cancersource ↗
◆Poster PresentationTLX250-CDx (Zircaix)FiledPresentation
TLX250-Px PET/CT impact on staging and clinical management in ccRCC ePoster at EANM
clear cell renal cell carcinomasource ↗
◆Poster PresentationTLX102Presentation
QDOSE allometry-guided human dosimetry of TLX102-Tx ePoster at EANM
◆Poster PresentationPresentation
Radioguided surgery based on internal conversion electron detection ePoster at EANM
▲Corporate ApprovalCorporate
Telix Board and ITM Shareholders holding over 90% approved the transaction as of signing
▲AcquisitionCorporate
Telix to acquire ITM for US$1.65B upfront plus up to US$700M contingent consideration
▲FDA ApprovalPixclaraApprovedFDA Decision
FDA approves Pixclara (floretyrosine F 18) for glioma PET imaging
glioma (brain cancer) imagingsource ↗
▲Enrollment CompleteIlluccixApprovedTrial
Enrollment completed in Phase 3 BiPASS study
prostate cancersource ↗
▲FDA Feedback ReceivedIlluccixApprovedFDA Meeting
Aligned with FDA on NDA pathway for BiPASS
prostate cancersource ↗
▲Product LaunchPixclaraApprovedPost-Market
First commercial doses of Pixclara administered
glioma imagingsource ↗
▲Enrollment CompleteIlluccixApprovedTrial
Patient enrollment nearing completion for Phase 3 BiPASS study
prostate cancer imagingsource ↗
◆CRL ResubmissionTLX250-CDx (Zircaix)FiledFDA Decision
Extension of BLA resubmission deadline granted for Zircaix
kidney cancer imagingsource ↗
◆Enrollment UpdateTLX591FiledTrial
Part 2 continues to enroll well in open regions
metastatic castration-resistant prostate cancersource ↗
▲FDA Filing AcceptedIlluccixApprovedRegulatory Filing
NDA for Illuccix accepted and under review by NMPA CDE
prostate cancer imagingsource ↗
▲EMA ValidationPixlumiEx-US Regulatory
Pixlumi MAA in Europe validated and accepted for review
glioma (brain cancer) imagingsource ↗
▲IND ClearancePixclaraApprovedIND
Pixclara Phase 3 IND cleared by FDA for brain metastases indication expansion
brain metastases diagnosissource ↗
▲Primary Endpoint MetTLX591FiledClinical Data
ProstACT Global Part 1 lead-in met safety and dosimetry objectives
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲FDA Feedback ReceivedTLX591FiledFDA Meeting
FDA confirmed safety data from Part 1 sufficient to progress Part 2 in U.S.
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Enrollment CompleteTLX597Trial
OPTIMAL-PSMA completed patient enrollment of 120 patients
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲First Patient DosedTLX597Trial
OPTIMAL-e dosed first patients
metastatic hormone sensitive prostate cancer (mHSPC)source ↗
▲First Patient DosedTLX101ApprovedTrial
Enrolled first patient cohort in Part 1 of IPAX BrIGHT
recurrent glioblastomasource ↗
▲Enrollment CompleteTLX101ApprovedTrial
Completed patient enrollment in IPAX-2
newly diagnosed glioblastomasource ↗
▲Manufacturing MilestoneCMC / Inspection
TMS Seneffe completed first GMP production run of lutetium-based therapeutic candidate
▲Full ResultsTLX400Clinical Data
Publication of long-term clinical outcomes from investigator-led study of TLX400-Tx in advanced/metastatic MTC
medullary thyroid carcinomasource ↗
▲PublicationTLX400Presentation
Publication of long-term clinical outcomes of TLX400-Tx in MTC in EJNMMI Research
medullary thyroid carcinomasource ↗
▲PublicationTLX591FiledPresentation
ProstACT SELECT study published in Cancers journal
advanced metastatic prostate cancersource ↗
▲First Patient DosedTLX-250Trial
First patient dosed in Phase 3 LUTEON trial of TLX250-Tx for ccRCC
relapsed or recurrent clear cell renal cell carcinoma (ccRCC)source ↗
◆Timing GuidanceTLX250-CDx (Zircaix)FiledPresentation
BLA resubmission for Zircaix expected shortly
kidney cancer imagingsource ↗
▲First Patient DosedTLX597Trial
First patients dosed in OPTIMAL-e Phase 2 study of TLX597-Tx for mHSPC
metastatic hormone-sensitive prostate cancersource ↗
▲Enrollment CompleteTLX591FiledTrial
Completed patient enrollment in Phase 3 study of TLX591-Px (Illuccix) for prostate cancer imaging in Japan
prostate cancer imagingsource ↗
Past FDA Catalysts and PDUFA Decisions
How TLX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-19 | TLX101-Tx (iodofalan-131I) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
9
Drugs Scored
rNPV / MCap
Top Drug
Top 6%
Small Cap(rank 42 of 687)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025)
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 131I-IPA Small MoleculesNCT05450744 | Neoplastic Disease | Phase 1 | ACTIVE NOT_RECRUITING | 12 | Jun 1, 2027 | ||||||
| 68Ga-PSMA-11 Small MoleculesNCT07052214 | PCA | Phase 3 | ACTIVE NOT_RECRUITING | 338 | Apr 1, 2027 | ||||||
| 153Sm-DOTMP Small MoleculesNCT07197645 | Bone Pain | Phase 1 | RECRUITING | 33 | Jul 5, 2027 | ||||||
| 177Lu-TLX591 Small MoleculesNCT06520345 | Metastatic Castration-resistant Prostate Cancer | Phase 3 | RECRUITING | 520 | Dec 1, 2030 | ||||||
| TLX250-CDx (Zircaix) BiologicsNCT06750419 | Clear Cell Renal Cell Carcinoma | Phase 3 | RECRUITING | 82 | Jun 30, 2026 | ||||||
| 177Lu-TLX250 Small MoleculesNCT07870746 | ccRCC | Phase 3 | NOT YET_RECRUITING | 80 | Oct 13, 2032 | ||||||
| 177Lu-TLX250 Small MoleculesNCT05868174 | Solid Tumor, Adult | Phase 1 | RECRUITING | 36 | Dec 1, 2026 | ||||||
| 89Zr-DFOsq-olaratumab BiologicsNCT06537596 | Soft Tissue Sarcoma | Phase 1 | RECRUITING | 50 | Dec 1, 2027 | ||||||
| TLX101 RadiopharmaceuticalsNCT07100730 | Neoplastic Disease | Phase 3 | RECRUITING | 50 | Nov 1, 2027 | ||||||
| 177Lu-DOTA-TLX591 BiologicsCompletedNCT05146973 | Prostate Cancer | Phase 2 | COMPLETED | 5 | Mar 24, 2024 | ||||||
| 177Lu-DOTA-TLX591 BiologicsCompletedNCT04786847 | Metastatic Prostate Cancer | Phase 1 | COMPLETED | 30 | Sep 30, 2023 | ||||||
| 64Cu-DOTA-TLX592 Small MoleculesCompletedNCT04726033 | Metastatic Prostate Cancer | Phase 1 | COMPLETED | 14 | Jan 29, 2024 | ||||||
| 89Zr-Girentuximab BiologicsCompletedNCT05861778 | Clear Cell Renal Cell Carcinoma | Phase 3 | COMPLETED | 310 | Nov 27, 2023 | ||||||
| 4-L-iodo-phenylalanine CompletedNCT03849105 | Glioblastoma Multiforme | Phase 1/2 | COMPLETED | 10 | Oct 31, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every TLX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TLX400-Tx | advanced medullary thyroid carcinoma (MTC) | 2026-07-23 | disease control rate: 80%; median progression free survival: 26 months; median overall survival: 42 monthsRead More | EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smith Darren CharltonOfficer (Group Chief Financial Officer) | Buy | 2,071 13,992 held | $6.97 | 09/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TLX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TLX for Q2 2026. | ||||
Ownership Trends
TLX Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
270.6K
Shares Sold Short
-23.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
381.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TLX ranks across every disease it competes in
Competitive Position is a premium feature
See how TLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTLX News
TLX▼ -1.4%today
Telix to Participate in UBS Global Biopharma Conference
Telix Pharmaceuticals will participate in the UBS Global Biopharma Conference in London on November 17, 2026. Dr. Christian Behrenbruch and Mr. Richard Valeix will engage in a fireside chat, which will be available via live webcast. Telix continues to advance its targeted theranostics for cancer treatment.
Read more →TLXCancellation of Appendix 2A
Telix Pharmaceuticals Limited announced the cancellation of share rights allocated in a previous announcement made on 28 October 2026. This cancellation means that these share rights will not be quoted as initially planned. An Appendix 3G will be lodged to provide further details regarding this cancellation.
Read more →TLXTelix Notice of General Meeting, Proxy Form and Online Guide
Telix Pharmaceuticals announced a General Meeting on December 1, 2026, to seek shareholder approval for its acquisition of ITM Isotope Technologies for $1.65 billion. The deal aims to strengthen Telix's position in the radiopharmaceutical market and is supported by over 93% of ITM shareholders. The acquisition includes potential milestone payments of up to $700 million.
Read more →TLX▼ -10.1%on this news
Telix Reports Third Quarter 2026 Financial Performance
Telix Pharmaceuticals reported a 19% increase in Q3 2026 revenue, reaching $245 million, driven by strong demand for its PSMA products. The FDA approved Pixclara for glioma imaging, marking a significant milestone. Additionally, Telix announced a merger with ITM, enhancing its radiopharmaceutical capabilities. The company expects FY 2026 revenue to exceed $1 billion.
Read more →TLXTelix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix Pharmaceuticals and Ekalia have formed a collaboration to produce astatine-211 in the U.S., enhancing access to this promising alpha-emitting isotope for targeted alpha therapy. The partnership aims to secure a long-term supply for Telix's therapeutic candidates, including TLX102-Tx for glioblastoma. The first production facility will be established in Pennsylvania, with potential for further expansion.
Read more →TLXTelix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM
Telix Pharmaceuticals will present 20 abstracts at the 39th Annual Congress of the EANM in Vienna from October 17-21, 2026. Key highlights include pivotal trials for TLX101-Tx in glioblastoma and TLX250-Tx in renal cancer. The company emphasizes its commitment to theranostics and will host a symposium on advancements in urologic oncology.
Read more →TLXProfound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical and Telix Pharmaceuticals have entered a co-education agreement to enhance prostate cancer care. This collaboration focuses on educating healthcare professionals about the complementary roles of Telix's PSMA-PET imaging technologies and Profound's MRI-guided TULSA-PRO platform. The initiative aims to improve patient selection and treatment planning, potentially expanding the market for TULSA-PRO.
Read more →TLXTelix to Host Capital Markets Day in Melbourne on November 4, 2026
Telix will host a Capital Markets Day in Melbourne on November 4, 2026. The event aims to update institutional investors and analysts on the company's commercial portfolio and late-stage pipeline. Key opinion leaders will also share insights on Telix's theranostic programs. Registration is required for in-person attendance.
Read more →TLXFirst Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
Telix Pharmaceuticals has announced the first administration of Pixclara, its FDA-approved imaging drug for glioma, in the U.S. This marks the beginning of its commercial availability, with doses administered at key medical centers in Cleveland and Indianapolis. Pixclara is designed to help differentiate recurrent glioma from treatment-related changes, addressing a critical need in brain cancer diagnostics.
Read more →TLXFDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
Telix Pharmaceuticals has received FDA Fast Track designation for its BiPASS program, which evaluates 68Ga-PSMA-PET imaging combined with MRI for pre-biopsy prostate cancer diagnosis. This designation acknowledges the program's potential to address unmet medical needs and may expedite the review process for the new drug application. The BiPASS study aims to enhance diagnostic accuracy and reduce unnecessary biopsies.
Read more →TLX▼ -10.2%on this news
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Telix Pharmaceuticals has announced a strategic merger with ITM Isotope Technologies, enhancing its position in the radiopharmaceutical sector. The merger aims to leverage ITM's leading isotope production capabilities and extensive therapeutic pipeline, particularly in targeted radionuclide therapy. The deal, valued at $1.65 billion, includes potential additional payments based on regulatory milestones. The transaction is subject to shareholder approval and expected to close by the end of FY 2026.
Read more →TLXFDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
The FDA has approved Pixclara, the first FET-PET imaging drug for glioma, enhancing diagnostic capabilities for brain cancer. This approval addresses a critical need for differentiating recurrent glioma from treatment-related changes in patients. Pixclara is recognized in international guidelines, marking a significant advancement in glioma care and precision medicine.
Read more →TLXTelix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
Telix Pharmaceuticals Limited will present at two upcoming healthcare conferences in New York. Dr. Christian Behrenbruch and Kevin Richardson will represent the company at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Both presentations will be available via live webcast.
Read more →TLX▲ +5.5%on this news
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix Pharmaceuticals has completed enrollment in its Phase 3 BiPASS study, which evaluates the effectiveness of its imaging agents, Illuccix and Gozellix, for prostate cancer detection before biopsy. The study enrolled 350 patients and aims to improve diagnostic accuracy while reducing unnecessary biopsies. Additionally, Telix has aligned with the FDA on a New Drug Application pathway to broaden access to PSMA-PET imaging.
Read more →TLXTelix Appoints David Gill as Chair
Telix Pharmaceuticals has appointed David Gill as the new Chair of the Board, effective immediately. Gill, who joined as a Non-Executive Director in May 2026, succeeds Dr. Mark Nelson, who will remain on the Board. With over 35 years of experience in the life sciences sector, Gill's leadership is expected to enhance Telix's growth and governance.
Read more →TLXTelix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Telix Pharmaceuticals reported strong financial results for the first half of 2026, achieving a 22% increase in revenue to US$477 million. The company highlighted significant growth in its Precision Medicine segment and successful collaborations, particularly with Regeneron. With a robust pipeline and multiple near-term catalysts, Telix is well-positioned for continued growth in the second half of the year.
Read more →TLXTelix to Host R&D Day in New York City on September 22, 2026
Telix Pharmaceuticals announced it will host an R&D Day on September 22, 2026, in New York City. The event aims to provide institutional investors and analysts with insights into Telix's therapeutic and precision medicine pipeline. Key leadership members will present, along with industry experts sharing their perspectives. Registration is required for in-person attendance.
Read more →TLXTelix H1 2026 Results: Investor Webcast Notification
Telix Pharmaceuticals Limited will release its financial results for the half-year ended June 30, 2026, on August 20, 2026. An investor webcast and conference call is scheduled for the same day. The company continues to advance its pipeline of targeted theranostics for cancer treatment, including investigational assets in pivotal-stage trials.
Read more →TLXEJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
Telix Pharmaceuticals announced promising results from a study on TLX400-Tx, a targeted therapy for advanced medullary thyroid carcinoma (MTC). The therapy showed an 80% disease control rate and acceptable safety in a real-world setting. With a median progression-free survival of 26 months, these findings support further investigation into TLX400-Tx's efficacy in larger trials.
Read more →TLX▼ -5.5%on this newsshared move
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
The publication of the ProstACT SELECT study results in the journal Cancers confirms the effectiveness of 68Ga-PSMA-PET imaging in selecting patients for TLX591-Tx therapy. TLX591-Tx, a PSMA-targeting rADC therapy, demonstrated a favorable safety profile and promising efficacy in advanced metastatic prostate cancer. The findings support ongoing evaluations in the ProstACT Global Phase 3 study.
Read more →About Telix Pharmaceuticals Limited
BIOPHARMAWATCH ELITE
Trade the next TLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime